Health Condition 1: null- Patients with chronic plaque psoriasis
Conditions
Interventions
Control Intervention1: NIL: NIL
Sponsors
Dr Bantwal Priya Baliga
Eligibility
Inclusion criteria
Inclusion criteria: CASES 1.Patients consenting to participate in the study. 2.All chronic plaque psoriasis adult patients above 18 years of age of either gender 3.All chronic plaque psoriasis patients diagnosed clinically or following biopsy will be included. 4. All chronic plaque psoriasis patients not treated with systemic immunosuppressant in the previous 3 months. 5. All chronic plaque psoriasis patient not treated with topical immunosuppressant in the previous 2 weeks. CONTROLS 1.Age and sex matched individuals without chronic plaque psoriasis.
Exclusion criteria
Exclusion criteria: CASES AND CONTROLS 1.Patients not consenting to participate in the study. 2.Patients with known autoimmune disease, malignancy, or serious chronic systemic disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Increased expression of miRNA223 in patients with chronic plaque psoriasisTimepoint: Expression of miRNA223 will be assessed within a period of 18 Months | — |
Secondary
| Measure | Time frame |
|---|---|
| The expression of miRNA223 can increase with the increase in severity of psoriasis.Timepoint: estimation of miRNA223 will be done after collection of all cases 18 months from the time of start of study | — |
Countries
India
Contacts
Public ContactDr Bantwal Priya Baliga
K S Hegde Medical Academy
Outcome results
None listed